ERBB2 and breast carcinoma: Recently, trastuzumab deruxtecan (T-DXd; DS-8201), as a novel anti-HER2 antibody drug conjugates (ADCs) have demonstrated a superior efficacy in breast cancer patients with HER-2 low expression [9].